No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HOLX Hologic
- 76.710
- -0.480-0.62%
Close Apr 24 16:00 ET
18.01BMarket Cap36.36P/E (TTM)
77.380High76.500Low963.15KVolume76.760Open77.190Pre Close73.99MTurnover0.41%Turnover Ratio41.92P/E (Static)234.73MShares87.88052wk High3.87P/B17.85BFloat Cap64.02052wk Low--Dividend TTM232.66MShs Float87.880Historical High--Div YieldTTM1.14%Amplitude0.750Historical Low76.820Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note
Goldman's Buybacks Basket: Buyback Growth Will Be 13% in 2024
Goldman Sachs analysts rebalanced their “buybacks basket” as 2024 buyback growth is forecasted to be 13%.
Is It Time To Consider Buying Hologic, Inc. (NASDAQ:HOLX)?
Is Weakness In Hologic, Inc. (NASDAQ:HOLX) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Hologic's (NASDAQ:HOLX) recent performance, when its stock has declined 2.8% over the past week. But if you pay close attention, you might gather that its
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?
Comments
Update
$Hologic(HOLX.US$ Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography 3 MINUTES AGO, 2:07 PM EDT VIA BUSINESSWIRE Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists Bayer and Hologic, Inc. (NASDAQ:HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two ...
1
Multiple insiders selling shares could be a red flag. The absence of insider purchases and significant selling over the last three months may suggest insiders believe the shares are overpriced. Despite high insider ownership, the lack of buying and significant selling raises concerns about the company.
Undervalued Hologic presents opportunity to accumulate stocks. Investors cautioned to consider financial health. Company's outlook suggests further growth not reflected in share price.
I've been eyeing the news on this sector and it finally gained some traction. I agree Dare is another good one
ColumnsToday's Pre-Market Stock Movers: LULU, TSLA, BBBY, Z and More
Gapping up
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
$Visa(V.US$ +1.1%, $MasterCard(MA.US$ +1.7% (Keybanc upgraded their ratings to overweight from from sector weight.)
$Zillow-C(Z.US$ +4% (Bank of America double upgraded the stock to buy, citing its improved growth outlook despite a challenging macroeconomic environment.)
$Hologic(HOLX.US$ +2.8% (The women's diagnostics provider reported fiscal first quarter revenue Sunday that topped its most recent guidance and Wall Str...
10
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg